Invention Grant
- Patent Title: Ebola virus disease vaccine taking human replication deficient adenovirus as vector
-
Application No.: US15760093Application Date: 2016-10-24
-
Publication No.: US10172932B2Publication Date: 2019-01-08
- Inventor: Wei Chen , Shipo Wu , Lihua Hou , Xiaohong Song , Jinlong Zhang , Ling Fu
- Applicant: Institute of Biotechnology, Academy of Military Medical Science, PLA
- Applicant Address: CN Beijing
- Assignee: Institute of Biotechnology, Academy of Military Medical Science, PLA
- Current Assignee: Institute of Biotechnology, Academy of Military Medical Science, PLA
- Current Assignee Address: CN Beijing
- Agency: Fox Rothschild LLP
- Priority: CN201610067289 20160131
- International Application: PCT/CN2016/103016 WO 20161024
- International Announcement: WO2017/128783 WO 20170803
- Main IPC: A61K39/00
- IPC: A61K39/00 ; C12N7/00 ; C12N15/86 ; C07K14/005 ; A61K48/00 ; A61K39/12 ; C12N15/861 ; A61P31/14

Abstract:
Provided are an Ebola virus envelope glycoprotein (that is GP protein) codon optimized nucleotide sequence, a human replication deficient recombinant adenovirus capable of expressing the nucleotide sequence, and applications in preparing a vaccine for preventing Ebola virus diseases. The nucleotide sequence takes a replication deficient 5 type adenovirus that is lack of E1 and E3 in a combined mode as a vector. HEK293 cells that integrate adenovirus E1 genes serve as a packaging cell line, and carried protective antigenic genes are codon optimized Zaire type Ebola virus Makona strain envelope glycoprotein genes. After the envelope glycoprotein genes are optimized by codon, the expression level in transfection cells is obviously improved.
Public/Granted literature
- US20180264100A1 Ebola Virus Disease Vaccine Taking Human Replication Deficient Adenovirus As Vector Public/Granted day:2018-09-20
Information query